Allergy Therapeutics (AGYTF) Stock Price, News & Analysis

Company Overview

Allergy Therapeutics plc is a biotechnology company focused on the development, manufacture and commercialization of allergen immunotherapy products. Its treatments are designed to address the underlying causes of allergic disease by gradually increasing a patient’s tolerance to specific allergens, rather than treating symptoms alone.

The company’s portfolio includes Pollinex Quattro, a short-course subcutaneous immunotherapy product for seasonal allergies such as grass, tree and ragweed pollen. Allergy Therapeutics also develops and supplies products targeting other allergens, including house dust mites, and conducts research into new immunotherapy approaches and allergy vaccines.

Headquartered in the United Kingdom, Allergy Therapeutics serves patients and healthcare professionals through commercial operations and distribution networks across a number of European markets, including Germany, Austria, Switzerland, Spain, Italy and the Netherlands. The company’s activities include clinical development, regulatory work, manufacturing and specialist allergy care support. Manuel Llobet has served as the company’s chief executive officer.

Key Stats

• Today's Range: $0.15 to $0.15
• 50-Day Range: $0.15 to $0.15
• 52-Week Range: $0.11 to $0.15
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $103.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 10/12/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:AGYTF
• Previous Symbol: NASDAQ:AGYTF
• CIK: N/A
• Web: www.allergytherapeutics.com
• Phone: 44-19-0384-4700
• Fax: N/A
• Employees: 612
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $71.22 million
• Price / Sales: 1.45
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.05) per share
• Price / Book: -3.00

Miscellaneous

• Outstanding Shares: 688,950,000
• Free Float: N/A
• Market Cap: $103.34 million
• Optionable: Not Optionable
• Beta: 0.81